The North America Ulcerative Colitis Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Ulcerative colitis is a type of inflammatory bowel disease that affects a large number of people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis. Ulcerative colitis can strike anyone at any age; however, it is most frequent in persons aged 15 to 30. The symptoms of ulcerative colitis differ from person to person, but they may include diarrhea, blood in the stool, and immunological response in the abdomen.
Ulcerative colitis, the most prevalent sign of inflammatory bowel disease, affects the colon (large intestine lining) and rectum. Diarrhea, belly pain/cramps, and rectum bleeding are the most common symptoms, but other signs and symptoms include sudden and unexplained weight loss, lack of appetite, joint pain, kidney stones, eye disease, thickening of the intestinal wall, blood infection (sepsis), and liver disease. Physical examination with procedures like colonoscopy, endoscopy, biopsy, CT scan, and blood test can be used to diagnose this condition.
The Centers for Disease Control and Prevention (CDC) estimates that between 2.2 and 14.3 cases per 100,000 people are discovered each year. In addition, according to a report published in 2014 by the Crohn's & Colitis Foundation of America (CCFA), 907,000 persons in the United States suffer from ulcerative colitis (statistics based on CCFA research conducted between 2011 and 2014). One of the crucial catalysts for the regional market is the existence of established key players and the growing patient pool of UC patients. Moreover, the sophisticated healthcare system is a key supporting factor for the regional market. In March 2019, Johnson & Johnson Services Inc. released additional findings from the Phase III UNIFI study, suggesting that STELARA is effective in adults with mild to severe ulcerative colitis.
The US market dominated the North America Ulcerative Colitis Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,501 million by 2028. The Canada market is experiencing a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 6.6% during (2022 - 2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Ulcerative Colitis Market is Estimated to reach $9 Billion by 2028, at a CAGR of 5.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
ByMolecule Type
By Disease Type
By Route of Administration
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Ulcerative Colitis Market, by Molecule Type
1.4.2 North America Ulcerative Colitis Market, by Disease Type
1.4.3 North America Ulcerative Colitis Market, by Route of Administration
1.4.4 North America Ulcerative Colitis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Ulcerative Colitis Market
Chapter 4. North America Ulcerative Colitis Market by Molecule Type
4.1 North America Small Molecules Market by Country
4.2 North America Biologics Market by Country
Chapter 5. North America Ulcerative Colitis Market by Disease Type
5.1 North America Mild Market by Country
5.2 North America Moderate Market by Country
5.3 North America Severe Market by Country
Chapter 6. North America Ulcerative Colitis Market by Route of Administration
6.1 North America Oral Market by Country
6.2 North America Injectables Market by Country
Chapter 7. North America Ulcerative Colitis Market by Country
7.1 US Ulcerative Colitis Market
7.1.1 US Ulcerative Colitis Market by Molecule Type
7.1.2 US Ulcerative Colitis Market by Disease Type
7.1.3 US Ulcerative Colitis Market by Route of Administration
7.2 Canada Ulcerative Colitis Market
7.2.1 Canada Ulcerative Colitis Market by Molecule Type
7.2.2 Canada Ulcerative Colitis Market by Disease Type
7.2.3 Canada Ulcerative Colitis Market by Route of Administration
7.3 Mexico Ulcerative Colitis Market
7.3.1 Mexico Ulcerative Colitis Market by Molecule Type
7.3.2 Mexico Ulcerative Colitis Market by Disease Type
7.3.3 Mexico Ulcerative Colitis Market by Route of Administration
7.4 Rest of North America Ulcerative Colitis Market
7.4.1 Rest of North America Ulcerative Colitis Market by Molecule Type
7.4.2 Rest of North America Ulcerative Colitis Market by Disease Type
7.4.3 Rest of North America Ulcerative Colitis Market by Route of Administration
Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Ajinomoto Co., Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental & Regional Analysis
8.2.4 Research & Development Expenses
8.3 AstraZeneca PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.4 GlaxoSmithKline PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.5 Johnson & Johnson
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental &Regional Analysis
8.5.4 Research & Development Expenses
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Pfizer, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Approvals and Trials:
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 InDex Pharmaceuticals Holding AB
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Recent strategies and developments:
8.9.3.1 Partnerships, Collaborations, and Agreements:
8.10. Eli Lilly And Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
TABLE 1 North America Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 2 North America Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 3 North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 4 North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 5 North America Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Biologics Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Biologics Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 10 North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 11 North America Mild Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Mild Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Moderate Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Moderate Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Severe Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Severe Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 18 North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 19 North America Oral Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Oral Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Injectables Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Injectables Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 25 US Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 26 US Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 27 US Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 28 US Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 29 US Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 30 US Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 31 US Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 32 US Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 33 Canada Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 34 Canada Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 35 Canada Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 36 Canada Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 37 Canada Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 Canada Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 Canada Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 40 Canada Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 41 Mexico Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 42 Mexico Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 43 Mexico Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 44 Mexico Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 45 Mexico Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 Mexico Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 Mexico Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 Mexico Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 Rest of North America Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 50 Rest of North America Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 51 Rest of North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 52 Rest of North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 53 Rest of North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 Rest of North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 Rest of North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 56 Rest of North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 57 Key Information – Abbott Laboratories
TABLE 58 Key information – Ajinomoto Co., Inc.
TABLE 59 KEY INFORMATION – ASTRAZENECA PLC
TABLE 60 Key Information – GlaxoSmithKline PLC
TABLE 61 Key information – Johnson & Johnson
TABLE 62 KEY INFORMATION - MERCK & CO., INC.
TABLE 63 Key Information – Pfizer, Inc.
TABLE 64 Key Information – Sanofi S.A.
TABLE 65 Key Information – InDex Pharmaceuticals Holding AB
TABLE 66 Key Information – Eli Lilly And Company
List of Figures
FIG 1 Methodology for the research